Whittier Trust Co. lessened its position in Novartis AG (NYSE:NVS) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 61,960 shares of the company’s stock after selling 1,832 shares during the period. Whittier Trust Co.’s holdings in Novartis were worth $5,317,000 as of its most recent filing with the SEC.
A number of other large investors have also recently modified their holdings of NVS. Matthew Goff Investment Advisor LLC increased its stake in Novartis by 7,454.1% in the third quarter. Matthew Goff Investment Advisor LLC now owns 2,945,178 shares of the company’s stock valued at $38,988,000 after purchasing an additional 2,906,190 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Novartis in the third quarter valued at approximately $87,734,000. Eagle Asset Management Inc. increased its stake in Novartis by 5,739.0% in the third quarter. Eagle Asset Management Inc. now owns 843,622 shares of the company’s stock valued at $72,686,000 after purchasing an additional 829,174 shares in the last quarter. Janus Henderson Group PLC increased its stake in Novartis by 29.3% in the third quarter. Janus Henderson Group PLC now owns 3,267,352 shares of the company’s stock valued at $281,515,000 after purchasing an additional 741,373 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Novartis by 526.2% in the third quarter. Bank of New York Mellon Corp now owns 635,797 shares of the company’s stock valued at $54,780,000 after purchasing an additional 534,268 shares in the last quarter. 10.99% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have commented on NVS shares. Wolfe Research started coverage on shares of Novartis in a research note on Tuesday, October 23rd. They issued an “outperform” rating for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research note on Tuesday, November 6th. Goldman Sachs Group raised shares of Novartis from a “neutral” rating to a “conviction-buy” rating in a research note on Friday, November 16th. Cowen raised shares of Novartis from a “market perform” rating to an “outperform” rating and set a $100.00 target price for the company in a research note on Monday, November 26th. Finally, Barclays downgraded shares of Novartis from an “equal weight” rating to a “sell” rating in a research note on Friday, December 7th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $90.94.
Shares of Novartis stock traded up $0.86 on Monday, hitting $89.88. The company had a trading volume of 2,351,443 shares, compared to its average volume of 2,114,598. The stock has a market capitalization of $207.62 billion, a PE ratio of 17.66, a price-to-earnings-growth ratio of 1.93 and a beta of 0.69. Novartis AG has a twelve month low of $72.30 and a twelve month high of $92.39. The company has a quick ratio of 0.97, a current ratio of 1.20 and a debt-to-equity ratio of 0.29.
Novartis (NYSE:NVS) last released its quarterly earnings results on Wednesday, January 30th. The company reported $1.24 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.33 by ($0.09). The company had revenue of $13.27 billion during the quarter, compared to analyst estimates of $13.33 billion. Novartis had a net margin of 24.30% and a return on equity of 15.66%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.21 EPS. Equities analysts anticipate that Novartis AG will post 5.43 EPS for the current fiscal year.
The business also recently declared an annual dividend, which will be paid on Wednesday, March 13th. Stockholders of record on Tuesday, March 5th will be issued a $2.8646 dividend. This represents a dividend yield of 3.27%. The ex-dividend date is Monday, March 4th. This is a boost from Novartis’s previous annual dividend of $2.33. Novartis’s dividend payout ratio is 37.52%.
WARNING: “Novartis AG (NVS) Holdings Reduced by Whittier Trust Co.” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2019/02/18/novartis-ag-nvs-holdings-reduced-by-whittier-trust-co.html.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Featured Story: How Do Investors Open a Backdoor Roth IRA?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.